Abstract

http://ssrn.com/abstract=2326245
 


 



The Impact of Marijuana Pharmaceuticals


John Robert Alfino


Independent

September 15, 2013


Abstract:     
FDA will soon approve Sativex, the first marijuana-based pharmaceutical. Sativex is a tipping point in the marijuana law and the politics of strict prohibition. The reclassification of marijuana under the Controlled Substances Act is in the financial interests of the American pharmaceutical industry. The availability of marijuana-based, or synthetic cannabinoid-based, pharmaceuticals will change the politics of marijuana prohibition.

Number of Pages in PDF File: 6

Keywords: marijuana, Sativex, cannabinoid

working papers series





Download This Paper

Date posted: September 16, 2013  

Suggested Citation

Alfino, John Robert, The Impact of Marijuana Pharmaceuticals (September 15, 2013). Available at SSRN: http://ssrn.com/abstract=2326245 or http://dx.doi.org/10.2139/ssrn.2326245

Contact Information

John Robert Alfino (Contact Author)
Independent ( email )
No Address Available
United States
Feedback to SSRN


Paper statistics
Abstract Views: 57
Downloads: 9

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo4 in 0.297 seconds